Review on SGK1, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
DNA/RNA

Description
The SGK1 gene is comprised of 14 coding exons (Ensembl).
Transcription
Sgk1 contains 28 distinct gt-ag introns, it presents 32 different mRNAs transcription products with 28 alternatively spliced variants and 4 unspliced forms. 8 probable alternative promoters have been identified, 10 non overlapping alternative last exons and 8 validated alternative polyadenylation sites (AceView). The SGK1 gene is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, and C. elegans (Gene ID: 6446, NCBI).
Protein
Note
The serum-and glucocorticoid-inducible kinase 1 (SGK1) was discovered as a gene regulated transcriptionally by serum-and glucocorticoids in rat mammary tumor cells (Firestone et al., 2003) .
Description
SGK1 is a member of the "AGC" subfamily (García Martínez and Alessi, 2008) . SGK1 activation is dependent on phosphorylation. mTOR was found to be the H-motif kinase that phosphorylates Sgk1 at S422 and PDK1 at T256 (Hong et al., 2008; Amato et al., 2007; Kobayashi and Cohen, 1999; Perrotti et al., 2001) . Sgk1 is involved in mediating growth factor-, insulin-, IL-2-and steroid-dependent survival signals (Lang et al., 2009a; Mikosz et al., 2001) .
Expression
SGK1 transcription is regulated by the glucocorticoid receptor (GR), the mineralocorticoid receptor (MR), the progesterone receptor (PR), the vitamin D receptor (VDR), the retinoid X receptor (RXR), the farnesoid X receptor (FXR), the sterol regulatory element binding protein (SREBP), peroxisome proliferator-activated receptor γ (PPARγ), the cAMP response element binding protein (CREB), the p53 tumor suppressor protein, the Sp1 transcription factor, the activating protein 1 (AP1), the activating transcription factor 6 (ATF6), the heat shock factor (HSF), reticuloendotheliosis viral oncogene homolog (c-Rel), nuclear factor κB (NFκB), signal transducers and activators of transcription (STAT), TGFβ dependent transcription factors SMAD3 and SMAD4, and fork-head activin signal transducer (FAST) (Lang et al., 2009a) .
Localisation
SGK presents a stimulus-dependent regulation for the subcellular localization. SGK actively shuttles between the nucleus (in S and G2/M) and the cytoplasm (in G1) in synchrony with the cell cycle (Buse et al., 1999) . The nuclear localization signal (NLS) of SGK (located at an external surface of the molecule) binds the importin-alpha nuclear import receptor regulating the nuclear-cytoplasmic shuttling (Firestone et al., 2003) . SGK-1 localizes in the mitochondria, under hyperosmotic stress, that permits access to physiologically appropriate mitochondrial interacting proteins and substrates, such as IF-1 and the F1F0-ATPase, as part of the cellular stressed induced program (O'Keeffe et al., 2013) . A significant fraction of SGK-1 is membraneassociated and ubiquitilated (Brickley et al., 2002) .
Function
SGK1 regulates different ion channels, transporters, transcription factors and enzyme: ion channels like ENaC (Faletti et al., 2002) , TRPV5, ROMK, Kv1.3, KCNE1/KCNQ1, GluR1, GluR6; carriers like NHE3, GLUT1, SGLT1, EAAT1, EAAT2, EAAT3, EAAT4, EAAT5, Na + -K + -ATPase. SGK1 regulates the activity of enzymes like glycogen synthase kinase-3, ubiquitin ligase Nedd4-2, phosphomannomutase-2 and transcription factors like forkhead transcription factor FKHRL1, betacatenin, nuclear factor kappaB. Moreover, SGK1 contributes to the regulation of transport, hormone release, neuroexcitability, cell proliferation, and apoptosis (Lang et al., 2006) . Sgk1 can phosphorylate and activate MDM2, driving p53 to degradation, protecting cells from stress dependent apoptosis (Amato et al., 2009 ). Sgk1 was demonstrated to interact with phosphomannomutase 2 (PMM2), inhibiting its activity, with and without insulin stimulus (Menniti et al., 2005) . Moreover, it was demonstrated that the 60 kDa Lysophospholipase (LysoLP) interacts with SGK1, and that the expression of LysoLP in Xenopus oocytes decreases membrane expression of ENaC, inhibiting basal and Sgk1-dependent activation of the channel (Menniti et al., 2010) . Sgk1 can regulates RANBP1 at the gene transcription level with functional consequences on microtubule stability and cell sensitivity to taxol (Amato et al., 2013) . Alternative initiation of transcription at -2981, -850 upstream of the transcription initiation site (+1) of the reference mRNA of SGK1 was studied. Transcription of three distinct splice variants are all markedly upregulated in tumor tissues but differentially up-regulated under differentiation or hypoxia.
Implicated in
Various cancers
Increased expression of SGK1 have been observed in colon cancer, myeloma, medulloblastoma, prostate cancer, ovarian tumors and non-small cell lung cancer . SGK1-sensitive implication in tumour growth include activation of K(+) channels and Ca(2+) channels, Na(+)/H(+) exchanger, amino acid transporters, glucose transporters, upregulation of the nuclear factor NFkappaB and beta-catenin and downregulation of the transcription factors Foxo3a/FKHRL1 and p53 . SGK1 phosphorylates MDM2 with consequent p53 ubiquitylation, and influences cell proliferation, survival, and differentiation (Amato et al., 2009) . In cancer cells, SGK1 up-regulates RanBP1, a major effector of the GTPase RAN, which in turn influences mitotic microtubule activity and decreases taxol sensitivity (Amato et al., 2013) . SGK1 expression mediated the phosphorylation of ERK2, then the MEK/ERK complexes formation during liver regeneration (Won et al., 2009 ). SGK1 negatively regulates stress-activated signaling through inhibition of SEK1 function (Kim et al., 2007) . SGK1 interferes with the binding of SEK1 to JNK1 and MEKK1 , down-regulates vinculin phosphorylation, which in turn may enhance migration via actin cytoskeleton redistribution . SGK1 influences the activity of channels and transporters, such as Ca2+ release-activated channels (ICRAC) Orai1/STIM and the K+ channel Kv1.3, influencing cell proliferation and cell death . SGK1 is a direct beta-catenin target gene and in colon cancer cells its up-regulation determines a SGK1 (serum/glucocorticoid regulated kinase 1) Menniti M, et al. Atlas Genet Cytogenet Oncol Haematol. 2015; 19(8) decrease of apoptosis through the down-regulation of Foxo3a activity (Dehner et al., 2008) . SGK-1 has significant homology with the serinethreonine Akt which is considered a relevant player in carcinogenesis, since its activation occurred in the majority of human tumors. Interestingly, some cancer cell lines that are resistant to Akt inhibition showed significant up-regulation of SGK1 expression (Sommer et al., 2013) .
Colorectal carcinoma
A recent study confirms the sensitivity of colon carcinoma to the expression of SGK1. Following deficiency of APC (adenoma polyposis coli) or chemical cancerogenesis, SGK1 knockout mice develop less intestinal tumours than their wild-type littermates and pharmacological SGK1 inhibition counteracts growth of cancer cells . SGK1 up-regulates RanBP1, a major effector of the GTPase RAN, which in turn influences mitotic microtubule activity and decreases taxol sensitivity in RKO colon carcinoma cells (Amato et al., 2013) .
Kidney cancer
In A-498 kidney cancer cells, IL-2 binding to its own receptor triggers a signal transduction pathway leading to the inhibition of proliferation and apoptosis. Inhibition of proliferation is associated with Erk1/2 dephosphorylation, whereas the survival signals appear to be mediated by Sgk1 activation (Amato et al., 2007) . 
Myeloma
Prostate cancer
Rauhala et al. showed the downregulation of mRNA and protein expressions of SGK, in prostate cancer. The expression of SGK was decreased in about half of the prostate carcinomas, whereas the expression was high in all non-malignant prostate epithelial cells (Rauhala et al., 2005) . Low espression of SGK1 is associated with higher tumor grade and increased cancer recurrence, and is a potential indicator of aberrant androgen receptor signaling. Glucocorticoid receptor expression increased with androgen deprivation, potentially providing a mechanism for the maintenance of androgen pathway signaling in these tumors (Szmulewitz et al., 2012) . Inhibition of SGK1 expression or activity antagonizes androgen-induced growth of the prostate cancer cell line LNCaP, suggesting that SGK1 might be a viable target for the treatment of prostate cancer (Sherk et al., 2008) .
Ovarian cancer
Sgk was identified like a critical FSH-regulated gene important for the proliferation and maturation of granulosa cells in the normal ovary (Richards, 1994) . Specific and reproducible gene expression changes occur in human ovarian tumors over time, following systemic administration of glucocorticoids. Induction of SGK1 gene expression in epithelial tumor cell lines inhibits chemotherapy-induced tumor cell apoptosis (Melhem et al., 2009 ). Sgk expression is lower in epithelial tumours, serous and mucinous cystadenocarcinomas, and also in normal pre-menopausal ovaries (Chu et al., 2002) .
Hypertension
There are different SGK1 gene variants that can influence blood pressure (Rao et al., 2013) , including the combination of polymorphisms in intron 6 [I6CC] and exon 8 [E8CC/CT] (Lang et al., 2006; Lang et al., 2009a) . The insulin probably stimulates renal tubular salt reabsorption through the activation of SGK1 with consequent renal salt retention and hypertension in type II diabetes (Lang et al., 2006; Lang et al., 2009a) .
Diabetes
SGK1 regulates the Na+ coupled glucose transporter SGLT1 (Lang et al., 2006) , the adipocyte differentiation and the adipogenesis (Di Pietro et al., 2010) . The I6CC/E8CC/CT SGK1 gene variant determines enhancement in body weight and prevalence of type 2 diabetes (Lang et al., 2009b) .
Thrombosis
SGK1 stimulates coagulation, through tissue factor expression (Lang et al., 2009a) and regulation of blood platelets by up-regulation of NFκB, and consequent expression of the platelet Ca2+ channel Orai1/STIM1, that predisposing to stroke (Dahlberg et al., 2011) and thrombosis (Borst et al., 2012) .
Autoimmune disease
SGK1 is involved in autoimmune disease, through up-regulation of the pathogenic IL-23-dependent interleukin (IL) 17-producing CD4+ helper T cells (TH17 cells) (Kleinewietfeld et al., 2013) . In affected tissues of inflammatory and fibrosing diseases was demonstrated an excessive expression of SGK1, like in lung fibrosis, diabetic nephropathy, glomerulonephritis, experimental nephrotic syndrome, obstructive nephropathy, liver scirrhosis,
